Ophthalmology is the branch of medical science that deals with the management and study of anatomy, physiology, and diseases related to the human eye. Globally, the incidence of eye disorders and vision loss are becoming major public health issues. Some of the major eye diseases include age-related macular degeneration, glaucoma, cataract, bulging eyes, diabetic macular edema, ocular hypertension, retinal detachment, uveitis, and refractive errors.
Cytomegalovirus retinitis refers to an eye disease caused by inflammation of the retina of eye. Cytomegalovirus is the causative agent of this disease. It is a herpes virus that attacks the photosensitive cells of retina. This disease spreads from one eye to another. Some common symptoms involved with cytomegalovirus retinitis are blurred vision, photophobia, blind spots and seeing floaters. If left untreated, cytomegalovirus retinitis leads to blindness.
Cytomegalovirus generally stays in humans, however it stays dormant. It generally affects people with weak immune system such as HIV-positive patients. Medication for cytomegalovirus retinitis is available in various forms such as capsules, solutions, implants and tablets. The global market for cytomegalovirus retinitis treatment is increasing at a significant rate due to increase in the incidence of cytomegalovirus retinitis cases and growing awareness for different types of eye diseases.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/3721
North America dominates the global market for cytomegalovirus retinitis treatment due to increasing incidence of cytomegalovirus retinitis cases and improved medical facilities in the region. Asia, followed with Europe, is expected to experience high growth rate in the next few years in the global cytomegalovirus retinitis treatment market.
China and India are expected to be the fastest growing cytomegalovirus retinitis treatment markets in Asia-Pacific region. Some of the key driving forces for cytomegalovirus retinitis treatment market in emerging countries are large pool of patients and rising government initiatives and support
Some of the other major factors driving the global cytomegalovirus retinitis treatment market are increasing prevalence of cytomegalovirus retinitis cases and improvement in the healthcare facilities. In addition, rising government initiatives towards healthcare infrastructure in developing countries are also fueling the growth of global cytomegalovirus retinitis treatment market.
Request Customization of this Report @ https://www.persistencemarketresearch.com/request-customization/3721
However, lack of awareness among people for different types of eye diseases and lack of healthcare insurance are some of the major factors restraining the global cytomegalovirus retinitis treatment market. In addition, rising healthcare cost in developing countries, such as India and China, is hampering affordability of healthcare facilities among the aging population. Majority of the population does not have access to primary healthcare services, attributable to poverty and absence of health insurance.
Growing demographics and economies in the developing countries such as India and China are expected to offer good opportunities for cytomegalovirus retinitis treatment market. In addition, innovation of some new products with focus on better efficacy is expected to offer good opportunity for cytomegalovirus retinitis treatment market.
However, lack of approved treatment guidelines by the World Health Organization is one of the key challenges faced by the global cytomegalovirus retinitis treatment market. One of the major trends that have been observed in the cytomegalovirus retinitis treatment market includes selling of off-label drugs for the treatment of cytomegalovirus retinitis.
For In-depth Competitive Analysis, Pre-Book Report Now @ https://www.persistencemarketresearch.com/checkout/3721
Some of the major companies dealing in the global cytomegalovirus retinitis treatment market are :
- F. Hoffmann-La Roche,
- Gilead Sciences and Hospira.
- Shire Plc, Auritec Pharmaceuticals,
- Chimerix Pharmaceuticals